Published online Feb 16, 2024. doi: 10.4253/wjge.v16.i2.72
Peer-review started: November 22, 2023
First decision: November 30, 2023
Revised: December 19, 2023
Accepted: December 25, 2023
Article in press: December 25, 2023
Published online: February 16, 2024
Processing time: 69 Days and 20.5 Hours
For cT1N0M0 esophageal cancer (EC), the current study has mainly focused on surgery and endoscopic submucosal dissection (ESD), while definitive chemoradiotherapy (d-CRT) is a complementary treatment for cT1N0M0 EC. Studies on estimating the therapeutic effect and safety of d-CRT, surgery and ESD are not sufficient, so this study is important.
Early-stage EC is currently increasing year by year, and its treatment methods are also changing rapidly. It is very important to choose the treatment methods with good prognosis and fewer complications, while some patients have the dilemma of treatment choice due to age, cost and other reasons. It is very important to summarize and compare the advantages and disadvantages of the existing treatment methods, which is very important for the health management of patients with EC.
By comparing the efficiency and safety of ESD, surgery and d-CRT for cT1N0M0 EC, to provide a clinical basis for the treatment selection of cT1N0M0 EC and to achieve better prognosis and quality of survival for EC.
We retrospectively analyzed the medical records, pathology, imaging and endoscopic findings, and follow-up results of the cT1N0M0 EC. We met the inclusion criteria and adjusted the effects of confounding factors using the inverse probability of treatment weighting method to conduct survival analysis, Cox proportional risk regression analysis, collected complications and costs, rescue measures after recurrence, and finally evaluated the efficacy and safety of cT1N0M0 EC patients receiving ESD, surgery and d-CRT.
Results showed that ESD had better survival outcomes, lower hospital costs and more acceptable occurrences of complications. This study provides a more comprehensive analysis of the efficacy and safety of current cT1N0M0 EC treatment patterns and provides new evidence for the use of ESD in cT1N0M0 EC. To our knowledge, our study is the first to compare the effects of all three treatments for cT1N0M0 EC. In addition, there are relatively few studies on d-CRT for cT1N0M0 EC patients, and our study can provide relevant evidence of d-CRT for cT1N0M0 EC, so it has a certain new innovation.
This is a first retrospective study to compare overall survival, recurrence-free survival and complication rates of ESD, surgery and d-CRT, and show that ESD attained better survival benefits and lower hospitalization costs than surgery and d-CRT, and they had similar complication rates. This study provides a more comprehensive analysis of the efficacy and safety of current cT1N0M0 EC treatment patterns and provides new evidence for the use of ESD in cT1N0M0 EC.
In the future, we will conduct a subgroup analysis of survival outcomes for the three therapies in cT1N0M0 EC patients, and investigate methods to reduce the occurrence of complications.